• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Fig Blockade of TGF


    Fig. 7. Blockade of TGF-βRI reduces CD73 expression in CeCa cells. CaSki (A) and HeLa (B) Nivolumab (1 × 105) were cultured with 1 mM Ado in the presence or absence of 25 μM SB505124, selective inhibitor of TGF-β type I receptors. After 96 h, CD73 expression on the cell membrane was analyzed by flow cytometry (A and B), and TGF-β1 content was analyzed by ELISA (C and D). Data are representative of three independent experiments, and the averages ± SEM are shown. Significant differences are indicated with respect to cells without treatment (basal expression) as *(p < 0.05), **(p < 0.005), and ***(p < 0.001).
    Appendix A. Supplementary data
    R. García-Rocha et al.
    J. Hernandez-Montes, C.A. Don-Lopez, V. Gutierrez-Serrano, I.J. Titla-Vilchis, M.C. Fuentes-Castaneda, A. Monroy-Mora, L.F. Jave-Suarez, R. Chacon-Salinas, L. Vallejo-Castillo, S.M. Perez-Tapia, A. Monroy-Garcia, Cervical cancer cells sup-press effector functions of cytotoxic T cells through the adenosinergic pathway, Cell. Immunol. 320 (2017) 46–55. [30] M.V. Sitkovsky, D. Lukashev, S. Apasov, H. Kojima, M. Koshiba, C. Caldwell,
    A.S. Kadish, G.L. Goldberg, Altered expression of transforming growth factor-beta 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix, Cancer 77 (6) (1996) 1107–1114. [44] C.W. Daniel, S.D. Robinson, Regulation of mammary growth and function by TGF-beta, Mol. Reprod. Dev. 32 (2) (1992) 145–151. [45] H.S. Wu, Y.F. Li, C.I. Chou, C.C. Yuan, M.W. Hung, L.C. Tsai, The concentration of serum transforming growth factor beta-1 (TGF-beta1) is decreased in cervical car-cinoma patients, Cancer Invest. 20 (1) (2002) 55–59. [46] D.R. Principe, J.A. Doll, J. Bauer, B. Jung, H.G. Munshi, L. Bartholin, B. Pasche, C. Lee, P.J. Grippo, TGF-beta: duality of function between tumor prevention and carcinogenesis, J. Natl. Cancer Inst. 106 (2) (2014) djt369. [47] I.V. Iancu, A. Botezatu, C.D. Goia-Rusanu, A. Stanescu, I. Huica, E. Nistor, G. Anton, A. Plesa, TGF-beta signalling pathway factors in HPV-induced cervical lesions, Roum. Arch. Microbiol. Immunol. 69 (3) (2010) 113–118. [48] S.P. Hung, M.H. Yang, K.F. Tseng, O.K. Lee, Hypoxia-induced secretion of TGF-beta1 in mesenchymal stem cell promotes breast cancer cell progression, Cell Transplant. 22 (10) (2013) 1869–1882. [49] A. Ohta, M. Sitkovsky, Role of G-protein-coupled adenosine receptors in down-regulation of inflammation and protection from tissue damage, Nature 414 (6866) (2001) 916–920. [50] B. Koscso, B. Csoka, Z. Selmeczy, L. Himer, P. Pacher, L. Virag, G. Hasko, Adenosine augments IL-10 production by microglial cells through an A2B adenosine receptor-mediated process, J. Immunol. 188 (1) (2012) 445–453. [51] F.S. Regateiro, S.P. Cobbold, H. Waldmann, CD73 and adenosine generation in the creation of regulatory microenvironments, Clin. Exp. Immunol. 171 (1) (2013) 1–7. [52] A.L. Smith, T.P. Robin, H.L. Ford, Molecular pathways: targeting the TGF-beta pathway for cancer therapy, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 18 (17) (2012) 4514–4521. [53] N. Cancer Genome Atlas Research, M. Albert Einstein College of, S. Analytical Biological, H. Barretos Cancer, M. Baylor College of, Nivolumab H. Beckman Research Institute of City of, A. Buck Institute for Research on, C. Canada's Michael Smith Genome Sciences, S. Harvard Medical, F.G.C.C. Helen, S. Research Institute at Christiana Care Health, B. HudsonAlpha Institute for, L.L.C. Ilsbio, M. Indiana University School of, V. Institute of Human, B. Institute for Systems, C. International Genomics, B. Leidos, H. Massachusetts General, U. McDonnell Genome Institute at Washington, W. Medical College of, C. Medical University of South, C. Memorial Sloan Kettering Cancer, C. Montefiore Medical, NantOmics, I. National Cancer, A.N. National Hospital, I. National Human Genome Research, S. National Institute of Environmental Health, D. National Institute on, D. Other Communication, L.H.S.C. Ontario Tumour Bank, O.I.f.C.R. Ontario Tumour Bank, T.O.H. Ontario Tumour Bank, H. Oregon, U. Science, C.-S.M.C. Samuel Oschin Comprehensive Cancer Institute, S.R.A. International, S. St Joseph's Candler Health, Eli, L.B.I.o.M.I.o.T. Edythe, U. Harvard, H. Research Institute at Nationwide Children's, U. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, B. University of, M.D.A.C. C. University of Texas, H. University of Abuja Teaching, B. University of Alabama at, I. University of California, C. University of California Santa, C. University of Kansas Medical, L. University of, C. University of New Mexico Health Sciences, H. University of North Carolina at Chapel, C. University of Oklahoma Health Sciences, P. University of, R.a.P.M.S. University of Sao Paulo, C. University of Southern, W. University of, M. University of Wisconsin School of, H. Public, I. Van Andel Research, L. Washington University in St, Integrated genomic and molecular characterization of cervical cancer, Nature 543(7645) (2017) 378–384.